Informatie:
Fout:
ID
32683
Beschrijving
Study ID: 107038 Clinical Study ID: LPL107038 Study Title: Study to Estimate the Dose Proportionality of the Enteric-Coated Freebase Formulation of SB-480848 Patient Level Data: Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: Tyrisa ,US Study Indication: Atherosclerosis
Trefwoorden
Versies (1)
- 12-11-18 12-11-18 -
Houder van rechten
GSK group of companies
Geüploaded op
12 november 2018
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Estimation of Dose Proportionality of Darapladib - 107038
Eligibility Question
- StudyEvent: ODM
Similar models
Eligibility Question
- StudyEvent: ODM
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Did the subject meet all the entry criteria?
Item
Did the subject meet all the entry criteria?
boolean
Do not admit he subject into this study if any Inclusion/Exclusion criteria is violated unless an exception has been granted by the GSK Medical Monitor and subject is continuing in the study. Please clarify the exemption(s) below
Item
Do not admit he subject into this study if any Inclusion/Exclusion criteria is violated unless an exception has been granted by the GSK Medical Monitor and subject is continuing in the study. Please clarify the exemption(s) below
text